Health care industry
Sanofi's High-Dose Flu Vaccine Delivers Superior Protection for Older Adults
Sanofi has announced new results from the FLUNITY-HD study, confirming that its high-dose influenza vaccine, Efluelda, offers significantly greater protection against hospitalisations in adults aged 65 and older. The study, published in The Lancet, included 466,320 participants across Denmark and Spain, making it the largest influenza vaccine effectiveness trial